PAI-1 interaction with sortilin-related receptor 1 is required for lung fibrosis
Authors:
- Thomas H. SissonTSThomas H. Sisson
- John J. OsterholzerJOJohn J. Osterholzer
- Lisa LeungLLLisa Leung
- Venkatesha BasrurVBVenkatesha Basrur
- Natalya SubbotinaNSNatalya Subbotina
- Mark WarnockMWMark Warnock
- Daniel TorrenteDTDaniel Torrente
- Ammara Q. VirkAVAmmara Q. Virk
- Sergey S. GutorSGSergey S. Gutor
- Jeffrey C. HorowitzJHJeffrey C. Horowitz
- Mary MiglioriniMMMary Migliorini
Open Access
- 29 April 2025
- journal article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (11)
Abstract
Mutation studies of plasminogen activator inhibitor 1 (PAI-1) have previously implied that PAI-1 promotes lung fibrosis via a vitronectin-dependent (VTN-dependent) mechanism. In the present study, employing 2 distinct murine fibrosis models and VTN-deficient mice, we found that VTN is not required for PAI-1 to drive lung scarring. This result suggested the existence of a profibrotic interaction involving the VTN-binding site on PAI-1 with an unidentified ligand. Using an unbiased proteomic approach, we identified sortilin-related receptor 1 (SorLA) as the most highly enriched PAI-1 binding partner in the fibrosing lung. Investigating the role of SorLA in pulmonary fibrosis demonstrated that deficiency of this protein protected against lung scarring in a murine model. We further found that SorLA is required for PAI-1 to promote scarring in mice, that both SorLA and PAI-1 protein levels are increased in human idiopathic pulmonary fibrosis (IPF) explants, and that these proteins are associated in IPF tissue. Finally, confocal microscopy showed that expression of SorLA in CHO cells increased cellular uptake of PAI-1, and these proteins colocalized in the cytoplasm. Together, these data elucidate a mechanism by which the potent profibrotic mediator PAI-1 drives lung fibrosis and implicate SorLA as a potential therapeutic target in IPF treatment.Keywords
All Related Versions
Funding Information
- U.S. Department of Veterans Affairs (Merit Review Award)
- National Heart, Lung, and Blood Institute (HL153056, HL163870, HL055374, HL007749)
- National Institute on Aging (AG074552)
- Quest for Breath (XX)
This publication has 58 references indexed in Scilit:
- Influence of PAI-1 on Adipose Tissue Growth and Metabolic Parameters in a Murine Model of Diet-Induced ObesityArteriosclerosis, Thrombosis, and Vascular Biology, 2000
- Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in miceBlood, 2000
- Expression of LR11, a Mosaic LDL Receptor Family Member, Is Markedly Increased in Atherosclerotic LesionsArteriosclerosis, Thrombosis, and Vascular Biology, 1999
- Plasminogen Activator Inhibitor-1 Contains a Cryptic High Affinity Binding Site for the Low Density Lipoprotein Receptor-related ProteinJournal of Biological Chemistry, 1998
- The serpin PAI-1 inhibits cell migration by blocking integrin αvβ3 binding to vitronectinNature, 1996
- Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene.Journal of Clinical Investigation, 1996
- Vitronectin is not essential for normal mammalian development and fertility.Proceedings of the National Academy of Sciences, 1995
- The somatomedin B domain of vitronectin. Structural requirements for the binding and stabilization of active type 1 plasminogen activator inhibitor.Journal of Biological Chemistry, 1994
- Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization.Journal of Clinical Investigation, 1993
- Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome.Journal of Clinical Investigation, 1989